KeypointsLong‐term topical therapy is the cornerstone to managing chronic rhinosinusitis (CRS).Current levels of compliance with nasal douching (ND) and intranasal corticosteroids (INCS) are likely to be poor.Clinicians in both primary and secondary care need to work together to encourage good compliance and ensure where possible guidelines are adhered to for best use of healthcare resources.BACKGROUNDChronic rhinosinusitis (CRS) is a common inflammatory disorder of the respiratory tract defined by the presence of either nasal blockage and/or nasal discharge as well as loss of smell and/or facial pain/pressure for 12 weeks or more; this must be corroborated with endoscopic findings (mucopus/polyps) and/or radiological findings (CT scan opacification in sinuses). Chronic rhinosinusitis affects a significant proportion of the adult population with a recent European study suggesting a prevalence of 11% in the UK. Longitudinal data from the Clinical Practice Research Datalink (CPRD) show that 1% these affected adults receive treatment from their GP each year with an average of 4 GP visits, and additionally this includes prescription of multiple medications with 91% receiving an antibiotic prescription. There are no NICE guidelines, and although international guidelines exist, familiarity and uptake of them is not quantified. These guidelines recommend both intranasal corticosteroids (INCS) and
Clinical Otolaryngology – Wiley
Published: Jan 1, 2018
Keywords: ; ; ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera